CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 114 enrolled
Drug / intervention
Seroguard +1 moredrug
Likely dose
Seroguard 0.41 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03660787
NCT03660787Phase 2Completed
CompareCT.gov

Phase II Multi-center Randomized Double-blind Placebo-controlled Efficacy and Dose Ranging Trial of the Drug Product Seroguard, Solution (JSC Pharmasyntez, Russia) Used for the Prevention of Pelvic Adhesions

Pharmasyntez·interventional·Posted Sep 7, 2018·Updated Jun 19, 2019

In Brief

A Phase 2 clinical trial evaluating Seroguard and Placebo for Adhesion. Completed, enrolled 114 participants across 14 sites.

Detailed Summary

This trial was a multi-center, double-blind, randomized, parallel group, placebo-controlled, phase II study in adult hospitalized female patients with the confirmed diagnosis of pelvic adhesive disease in Study centres in Russia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdhesion
CountriesRussia
CollaboratorsCromos Pharma LLC

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 7, 2018
Enrollment StartMay 4, 2017
Primary CompletionJan 23, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.8 years ago

Interventions

Seroguarddrug

Seroguard 0.41 g/L solution

Placebodrug

Saline